MedTrace Logo

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

NCT06733441 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-10-10

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.

Conditions

Interventions

DRUG

TLN-254

TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.

DRUG

TLN-254

TLN-254 will be administered orally at a specified dose on specified days.

Sponsors & Collaborators

  • Treeline Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2026-11-15
Completion
2028-11-15
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06733441 on ClinicalTrials.gov